October 16, 2015

Novocure to Report Third Quarter 2015 Financial Results on Monday, October 26

October 16, 2015 11:54 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today that it will report financial results for the third quarter of 2015 on Monday, October 26, 2015 after the close… Read More
learn more
October 16, 2015

Novocure to Offer On Demand Optune Certification Training for the Radiation Oncology Community at ASTRO 2015

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients October 16, 2015 05:04 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel… Read More
learn more
October 9, 2015

ADDING MULTIMEDIA FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma

Optune is the first FDA-approved therapy in more than a decade to demonstrate statistically significant extension of survival in newly diagnosed glioblastoma patients The EF-14 trial achieved statistically significant extension of both progression-free survival and overall survival in newly diagnosed glioblastoma with a 50% increase… Read More
learn more
October 7, 2015

NovoCure Limited Announces Closing of Initial Public Offering

October 07, 2015 04:05 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the closing of its initial public offering of 7,500,000 ordinary shares at a price to the public of $22… Read More
learn more
October 5, 2015

Novocure Announces CE Mark and First Patient Use of Second Generation Optune System

The newly designed, second generation Optune system incorporates state of the art digital technology and is more than 50% lighter and 50% smaller than the first generation system Second generation Optune, including battery (Photo: Business Wire) Download… Read More
learn more
October 2, 2015

NovoCure Limited Announces Launch of Initial Public Offering

October 01, 2015 09:07 PM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited, a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common stock, including 7,500,000 shares to be sold by… Read More
learn more
September 21, 2015

NovoCure Limited Announces Launch of Initial Public Offering

September 21, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–NovoCure Limited, a commercial stage oncology company pioneering a novel therapy for solid tumors, announced today the launch of its initial public offering of 12,500,000 shares of its common stock, including 7,500,000 shares to be sold by… Read More
learn more
September 9, 2015

Novocure to Present the Latest Data from the EF-14 Clinical Trial in Newly Diagnosed GBM at the 15th Interim Meeting of the World Federation of Neurosurgical Societies

September 09, 2015 07:00 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the latest data from the EF-14 randomized phase 3 trial of Tumor Treating Fields (TTFields) in newly diagnosed glioblastoma (GBM) will be presented by Professor Zvi Ram, Head… Read More
learn more
September 8, 2015

Novocure Announces Optune Now Available at more than 200 Leading Cancer Centers across the United States

Optune, a Tumor Treating Fields delivery system, provides a novel, non-invasive treatment for recurrent glioblastoma, the most common and deadly malignant primary brain cancer More than 270 clinical centers have been certified globally, primarily in the United States, Japan and Germany September 08, 2015… Read More
learn more
September 4, 2015

Novocure to Present Clinical Trial Designs and Preclinical Data on Tumor Treating Fields at the 16th World Conference on Lung Cancer

September 04, 2015 10:24 AM Eastern Daylight Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that its ongoing and future clinical trial designs in lung cancer will be presented at the 16th World Conference on Lung Cancer (WCLC). The WCLC is the world’s largest… Read More
learn more